Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.
about
Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsEffectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Hepatitis C treatment initiation in HIV-HCV coinfected patients.Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population.Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.Engagement in the Hepatitis C Care Cascade Among Homeless Veterans, 2015.HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Editorial: Veterans' health.The health and wellbeing needs of veterans: a rapid review.Impact of sustained virologic response on chronic kidney disease progression in hepatitis C.Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.Hyperammonemia in Hepatic EncephalopathyImpact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
P2860
Q28546457-57546121-0C31-4BC5-B21B-C41D516D5FA9Q28550423-C6408F95-4D42-4897-8B8A-95EFD2579153Q30841159-B5D61C94-C83C-4F1D-8782-7EAA95BF2876Q36083688-D79C605B-75EF-47FF-8ACC-3C9DD5B291ADQ36219877-640DA332-2F09-4E89-AB66-24661C275A6FQ38405059-011EE481-B330-4563-83D5-09BDE958DC05Q38745903-51A5F30C-7F0B-4F1A-9DD5-85A123338D5EQ38854076-5EE21825-0989-4D6E-8E3B-2DDDD804B1DBQ38991902-F64F204B-4BFE-4EFC-ACE8-7383068B903FQ40078740-7622D120-E51B-45AD-8E19-796583FF4AD7Q40597366-6B7FA748-F252-4277-A0BA-9621B7A24A45Q45328358-0D35D3F8-2714-4846-B5D0-016BFD943C15Q47148421-EBF00728-F6A2-440A-8230-BFAF1A652B7EQ47550115-5FD099C2-DF13-450F-8013-84B58C7BAE49Q54213589-77FCA32E-4A02-403F-9455-EF443E5FB001Q57300676-4696FE75-545E-4874-A4FF-9AE9663F0C2AQ58541835-B21D5017-9CC8-4990-A231-834B9657B1F2
P2860
Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Prevalence and treatment of ch ...... epartment of Veterans Affairs.
@en
type
label
Prevalence and treatment of ch ...... epartment of Veterans Affairs.
@en
prefLabel
Prevalence and treatment of ch ...... epartment of Veterans Affairs.
@en
P2860
P356
P1476
Prevalence and treatment of ch ...... epartment of Veterans Affairs.
@en
P2093
George N Ioannou
Lauren A Beste
P2860
P304
P356
10.1093/EPIREV/MXU002
P577
2015-01-19T00:00:00Z